Transcranial Magnetic Stimulation for Innovative Brain Research
The Brainsway* patented breakthrough Deep TMS, or Transcranial Magnetic Stimulation, launches a new era in brain stimulation and research. Brainsway offers a non-invasive, effective* depression treatment that activates deep brain structures. This is achieved using directed electromagnetic fields which generate excitation or inhibition of neurons deep inside the brain.
Brainsway's repetitive transcranial magnetic stimulation, is based on patents filed by the U.S. National Institutes of Health (NIH) and the company. The treatment was embraced by the international academic community, and is implemented in over 60 clinical trials in leading institutions worldwide.
Unique, Patented Coil Structure
Brainsway's Transcranial Magnetic Stimulation treatment is based on the H Coil, featuring a novel patented structure which maximizes electrical stimulation of deep brain regions. Unique features of the coil design include:
- Coil elements tangential to the head and close to target brain regions
- Flexible base suited to head shape
- Convergence of numerous electric pulses from various directions
- Coil elements parallel to target bundles
- Location of return paths of electrical impulses remote from target area
Brainsway repetitive transcranial magnetic stimulation technology is based on a patent registered by the U.S. National Institutes of Health (NIH). Brainsway has an exclusive license from the NIH for both the patent and the technology.
Repetitive Transcranial Magnetic Stimulation Optimized for Research
Brainsway's Deep TMS technology includes a double blind system for easily conducting randomized studies. The system features smart cards which are randomized between the patients. When the treatment begins, the patient’s individual smart card is inserted into the card reader, automatically activating either the real coil or the sham coil, which are both located within the patient's head set. Both coils produce scalp sensations and acoustic artifact which are similar, so that neither the patient nor the caregiver knows whether the treatment is real.
Applicable for a Variety of Clinical & Neuroscience Studies
Brainsway's repetitive transcranial magnetic stimulation technology can stimulate a wide variety of brain regions and networks.
Transcranial Magnetic Stimulation can easily be applied to diverse clinical applications by designing coils targeting different locations, depths, directionalities & morphologies which can impact target neuronal structures, and by using different protocols during the treatment.
Brain regions which have been stimulated in various studies using Brainsway's technology include the following:
Lateral and medial prefrontal cortex (PFC) including ventral PFC
Right & left Insular cortex and entorhinal cortex
Anterior cingulate cortex
Posterior cingulate cortex
Lateral and medial motor cortex, including deeper leg motor cortex
Supplementary motor area
Right and left temporal cortex structures, including fusiform face area (FFA) & superior temporal sulcus (STS)
Parietal cortex regions
Occipital cortex regions
Deep Stimulation – Enhanced Effect
Studies have proven that the depth and wide range of brain stimulation impact the results in a significant and positive way.
- “Many behavioral manifestations of neurological and psychiatric diseases are not solely the result of abnormality in one isolated brain region but represent alterations in brain networks and connectivity.” (Fox et al. Neurolmage 2012(
- "Deeper (ventral) PFC structures have significantly more connections with other reward system sites compared to superficial PFC". (Leh et al., 2007)
- “There is significant inter-individual variability in the exact location of DLPFC sites having functional connectivity with subgenual cingulate “(Fox et al. Neuroimage 2012)
- “Effective response to standard TMS in MDD is strongly correlated with resting state functional connectivity between DLPFC stimulation sites and subgenual cingulate “(Fox et al. Biol. Psychiatry 2012).
- “Individualized targeting becomes less important with larger stimulation field sizes” (Fox et al. Biol. Psychiatry 2012)
Brainsway Deep TMS, has been cleared by the FDA** for patients who tried any number of antidepressants with no improvement (in the current depressive episode). The FDA indication is based on a unique long-term 16-week double-blind placebo-controlled multi-center study which enrolled over 200 subjects, and reported a marked decline in HDRS-21 scores, as well as significant remission (32.6%) and response (38.4%) rates at the primary endpoint of the study after 4 weeks of acute treatment. In the study, Brainsway's treatment was proved to be safe, and the treatment was well tolerated by the majority of the study subjects.
** FDA 510(k) No. K122288